EURACTIV Trump’s MFN drug pricing impact still unclear in Denmark and Sweden [Advocacy Lab]
Denmark and Sweden are assessing how Trump’s 'Most Favoured Nation' push is affecting medicine access, now and long-term, despite safeguards in their value-based models